External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>TBPH prioritizes shareholder value and is trading at a discount to its NAV</li><li>The company is an attractive investment opportunity for value investors</li><li>TBPH has a strong focus on maximizing shareholder value, valuable assets, and potential for significant upside</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

TBPH prioritizes shareholder value and is trading at a discount to its NAVThe company is an attractive investment opportunity for value investorsTBPH has a strong focus on maximizing shareholder value, valuable assets, and potential for significant upsideThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Theravance Biopharma Inc (TBPH) - Tuesday, Jul 9, 2024

United States

Theravance Biopharma Inc focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Theravance Biopharma (TBPH US)

Theravance Biopharma Inc (TBPH) - Tuesday, Jul 9, 2024

TBPH prioritizes shareholder value and is trading at a discount to its NAV. The company is an attractive investment opportunity for value investors

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)